{"id":390732,"date":"2018-03-05T00:00:00","date_gmt":"2018-03-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0004-2018-biopharma-crohns-disease-unmet-need-us-eu-2018\/"},"modified":"2026-03-31T10:48:52","modified_gmt":"2026-03-31T10:48:52","slug":"unneim0004-2018-biopharma-crohns-disease-unmet-need-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0004-2018-biopharma-crohns-disease-unmet-need-us-eu-2018\/","title":{"rendered":"Crohn&#8217;s Disease | Unmet Need | US\/EU | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The moderate to severe Crohn\u2019s disease (<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>) therapy market presents an\u00a0attractive commercial opportunity for new, effective treatments. Tumor necrosis factor-alpha (<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1) inhibitors (e.g., Remicade, Humira) have advanced the treatment of moderate to severe\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0by offering improved efficacy over conventional therapies; however, these agents still have safety risks and efficacy limitations. Novel biological agents with non-TNF inhibitor mechanisms of action (i.e., Takeda\u2019s Entyvio, approved in 2014, and Janssen\u2019s Stelara, approved in 2016) have expanded the treatment options for moderate to severe\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>, but significant needs remain, especially for patients refractory to available therapies.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for moderate to severe\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>?<\/li>\n<li>What drug attributes are key influencers on physician prescribing behavior, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for moderate to severe\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in moderate to severe\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 60 U.S. and 32 European gastroenterologists fielded in December 2017 and January 2018<\/p>\n<p><strong>Key companies:<\/strong>\u00a0AbbVie, Galapagos NV, Gilead, Janssen, Merck, Takeda, TiGenix<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Humira, Remicade, Stelara, Entyvio, Filgotinib, Cx-601, Risankizumab<\/p>\n","protected":false},"template":"","class_list":["post-390732","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390732\/revisions"}],"predecessor-version":[{"id":393856,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390732\/revisions\/393856"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}